Aditxt (NASDAQ:ADTX – Get Free Report) and Verastem (NASDAQ:VSTM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Profitability
This table compares Aditxt and Verastem’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Aditxt | N/A | -615.43% | -157.59% |
Verastem | N/A | -194.05% | -64.48% |
Risk and Volatility
Aditxt has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Aditxt | 0 | 0 | 0 | 0 | N/A |
Verastem | 0 | 0 | 8 | 0 | 3.00 |
Verastem has a consensus price target of $14.57, indicating a potential upside of 326.07%. Given Verastem’s higher possible upside, analysts plainly believe Verastem is more favorable than Aditxt.
Institutional and Insider Ownership
15.5% of Aditxt shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 1.2% of Aditxt shares are held by company insiders. Comparatively, 2.2% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Aditxt and Verastem”s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Aditxt | $329,739.00 | 6.17 | -$32.38 million | N/A | N/A |
Verastem | $2.60 million | 52.93 | -$87.37 million | ($3.34) | -1.02 |
Aditxt has higher earnings, but lower revenue than Verastem.
Summary
Verastem beats Aditxt on 8 of the 10 factors compared between the two stocks.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
About Verastem
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.